Journal article
Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease
Abstract
Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that rivaroxaban plus aspirin reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD). We explored whether CHA2DS2-VASc or CHADS2 scores, well-validated tools for assessing risk of thromboembolic events in atrial fibrillation, can identify vascular …
Authors
Sen J; Tonkin A; Varigos J; Fonguh S; Berkowitz SD; Yusuf S; Verhamme P; Vanassche T; Anand SS; Fox KAA
Journal
International Journal of Cardiology, Vol. 337, , pp. 9–15
Publisher
Elsevier
Publication Date
August 2021
DOI
10.1016/j.ijcard.2021.04.067
ISSN
0167-5273